Holen Sie sich die Stockscreener-App
27.28
1.19%
0.32
Vorhandelsmarkt:
27.26
-0.02
-0.07%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$26.96
Offen:
$27.18
24-Stunden-Volumen:
37.52M
Relative Volume:
0.83
Marktkapitalisierung:
$155.18B
Einnahmen:
$62.58B
Nettoeinkommen (Verlust:
$7.79B
KGV:
20.13
EPS:
1.3551
Netto-Cashflow:
$9.08B
1W Leistung:
-0.15%
1M Leistung:
+0.70%
6M Leistung:
+15.59%
1J Leistung:
+6.77%
1-Tages-Spanne:
$27.04
$27.53
1-Wochen-Bereich:
$26.44
$27.73
52-Wochen-Spanne:
$20.91
$27.94
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.28 | 155.18B | 62.58B | 7.79B | 9.08B | 1.3551 |
LLY
Lilly Eli Co
|
916.31 | 818.59B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
239.93 | 577.90B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
207.18 | 366.33B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.37 | 295.13B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
187.14 | 290.22B | 58.80B | 10.24B | 8.98B | 3.2788 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | Argus | Hold → Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2026-02-20 | Eingeleitet | Barclays | Underweight |
| 2026-02-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer Lyme Vaccine Readout Adds New Angle To Valuation Debate - simplywall.st
After Five Years of Sluggish Performance, Pfizer Finds Renewed Hope in High Dividends and Clinical Data - NAI500
Lyme disease vaccine 70 percent effective: Pfizer - MSN
Pfizer Inc. stock steady as Guggenheim hikes target to $36 amid Lyme vaccine Phase 3 success - AD HOC NEWS
Is Pfizer Stock a Buy After This Win? - The Globe and Mail
Pfizer (NYSE:PFE) Shares Up 1.2% After Analyst Upgrade - MarketBeat
Pfizer Options Spot-On: On March 25th, 76,121 Contracts Were Traded, With 2.36 Million Open Interest - Moomoo
Pfizer Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Pfizer/Metsera wins Matter of the Year at GCR Awards - Global Competition Review
Pfizer Inc. (PFE) Announces Positive Topline Results From Phase 3 TALAPRO-3 Study of TALZENNA® - Yahoo Finance
A Lyme Disease Vaccine Is Coming, But Experts Warn of a Major Catch in Pfizer’s Research - inc.com
Pfizer: Undervalued High-Yield Giant With A Pipeline Built For The Next Decade (NYSE:PFE) - Seeking Alpha
Pfizer's trispecific antibody shows promise against eczema - BioXconomy
Pensionfund Sabic Makes New $1.86 Million Investment in Pfizer Inc. $PFE - MarketBeat
Pfizer's Comirnaty Vaccine Variant-Adapted for 2025/2026 Season Gains Global Launch Momentum Amid Ob - AD HOC NEWS
Oil Volatility Shakes Markets – Life Sciences Stocks Back in Focus: Bayer, Vidac Pharma, Valneva, Novo Nordisk, and Pfizer - news.financial
Pfizer: Time To Buy The Turnaround (NYSE:PFE) - Seeking Alpha
Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts - BioSpace
Pfizer Inc. stock steady amid Guggenheim target hike to $36 and fresh Lyme vaccine data as analysts - AD HOC NEWS
Doctors say Pfizer's Lyme disease vaccine trial results 'encouraging' after more than 70% efficacy shown - abcnews.com
Doctors say Pfizer’s Lyme disease vaccine trial results ‘encouraging’ after more than 70% efficacy shown - Rural Radio Network
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN - GlobeNewswire Inc.
Pfizer Options Spot-On: On March 24th, 87,620 Contracts Were Traded, With 2.32 Million Open Interest - Moomoo
Pfizer Inc. stock navigates mini-tender warning and Guggenheim target hike amid pipeline optimism - AD HOC NEWS
Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial - 24/7 Wall St.
Pfizer Reports 73% Lyme Vaccine Efficacy as Trial Results Complicate Outlook - TradingView
Press Release: Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call With Analysts - Moomoo
Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Pfizer Inc. stock faces mini-tender warning amid Guggenheim target hike and valuation debate - AD HOC NEWS
Pfizer (NYSE:PFE) Price Target Raised to $36.00 - MarketBeat
Guggenheim Raises Pfizer (PFE) Price Target to $36 with a Buy Ra - GuruFocus
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Guggenheim raises Pfizer stock price target on drug trial outlook - Investing.com
Pfizer Inc. $PFE Shares Acquired by SG Americas Securities LLC - MarketBeat
Park Place Capital Corp Trims Position in Pfizer Inc. $PFE - MarketBeat
PFIZER INC : Jefferies keeps its Buy rating - marketscreener.com
Guggenheim Adjusts Pfizer's PT to $36 From $35, Keeps Buy Rating - marketscreener.com
E. Ohman J or Asset Management AB Purchases Shares of 140,617 Pfizer Inc. $PFE - MarketBeat
Anti Venom Market Set for Significant Growth| Pfizer, Inc. and Merck & Co. - openPR.com
Lyme disease vaccine shows 70 percent efficacy, Pfizer says - The Washington Post
Pfizer announces promising trial results for Lyme disease vaccine - WWMT
Pfizer Lyme Disease Vaccine Shows 70% Efficacy, But Misses Statistical Goal - HuffPost
Pfizer’s Lyme disease vaccine candidate shows promising results - The Hill
Pfizer working to get approval on new Lyme disease vaccine. Expert says tick activity rising in New England. - CBS News
Pfizer Lyme Vaccine Data Adds New Angle To Vaccine Portfolio Story - Yahoo Finance
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial - WSJ
Pfizer to seek FDA approval for Lyme vaccine as CT report shows ticks are more abundant than ever - CT Insider
Pfizer Options Spot-On: On March 23rd, 129.03K Contracts Were Traded, With 2.92 Million Open Interest - Moomoo
Pfizer Stock Is Doing Something It Hasn't Done Since 2022 - The Globe and Mail
Valneva (NASDAQ: VALN) and Pfizer report over 70% efficacy for Phase 3 Lyme disease vaccine - Stock Titan
Is Pfizer (PFE) Offering Value After Its Post Covid Portfolio Shift And Mixed Returns? - simplywall.st
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.52%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):